<DOC>
	<DOCNO>NCT01636271</DOCNO>
	<brief_summary>The overall objective integrate analysis evaluate clinical safety efficacy long-term treatment darapladib enteric coat tablet , 160mg , compare placebo add standard care subject clinical manifestation cardiovascular disease ( chronic coronary heart disease ( CHD ) post Acute Coronary Syndrome ( ACS ) ) . With respect efficacy , key purpose integrated analysis evaluate effect darapladib follow endpoint : urgent coronary revascularization myoacrdial ischemia , fatal/non-fatal stroke , time subsequent Major Adverse Cardiovascular Event ( MACE ) , heart failure require hospitalization . The first occurrent MACE , Major total coronary event well individual component MACE also evaluate descriptively .</brief_summary>
	<brief_title>SB-480848 Major Adverse Cardiovascular Events - Integrated Summary Efficacy Safety From STABILITY Trial ( LPL100601 ) SOLID-TIMI-52 Trial ( SB-480848/033 )</brief_title>
	<detailed_description>The objective integrate safety analysis characterize safety profile darapladib subject clinical manifestation cardiovascular disease ( chronic coronary heart disease ( CHD ) post Acute Coronary Syndrome ( ACS ) ) . The purpose integrate efficacy analysis test effect darapladib select endpoint part test hierarchy associate individual study , namely : urgent coronary revascularization myocardial ischemia , stroke , subsequent MACE , heart failure require hospitalization , For endpoint , intent integrate analysis provide increase precision estimate effect darapladib .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>This integrate analysis therefore inclusion criterion applicable . This integrated analysis therefore exclusion criterion applicable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>CV Risk</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Acute coronary syndrome</keyword>
</DOC>